Tandem Diabetes Care, Inc. (NASDAQ:TNDM) COO Acquires $190,948.56 in Stock

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) COO Jean-Claude Kyrillos acquired 10,538 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were acquired at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the transaction, the chief operating officer now owns 10,538 shares of the company’s stock, valued at approximately $190,948.56. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Tandem Diabetes Care Stock Down 1.5 %

Tandem Diabetes Care stock traded down $0.27 during trading on Tuesday, hitting $17.89. 3,730,117 shares of the company were exchanged, compared to its average volume of 1,477,873. The company has a market capitalization of $1.19 billion, a P/E ratio of -9.27 and a beta of 1.45. The business’s 50 day moving average is $32.80 and its 200 day moving average is $35.29. Tandem Diabetes Care, Inc. has a 52 week low of $17.36 and a 52 week high of $53.69. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29.

Analyst Ratings Changes

A number of equities research analysts have issued reports on TNDM shares. Royal Bank of Canada decreased their target price on Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. Morgan Stanley downgraded shares of Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $45.00 to $22.00 in a report on Wednesday, March 5th. Robert W. Baird dropped their target price on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th. Wells Fargo & Company reissued an “equal weight” rating and set a $22.00 target price (down previously from $38.00) on shares of Tandem Diabetes Care in a research report on Monday, March 3rd. Finally, Citigroup downgraded Tandem Diabetes Care from a “buy” rating to a “neutral” rating and lowered their price target for the company from $35.00 to $24.00 in a research report on Tuesday, March 4th. Eight equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, Tandem Diabetes Care has a consensus rating of “Moderate Buy” and an average target price of $45.38.

Hedge Funds Weigh In On Tandem Diabetes Care

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Connective Capital Management LLC purchased a new position in shares of Tandem Diabetes Care during the 4th quarter valued at $611,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Tandem Diabetes Care by 20.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 177,739 shares of the medical device company’s stock valued at $6,402,000 after acquiring an additional 30,133 shares during the period. Two Sigma Investments LP lifted its holdings in Tandem Diabetes Care by 4.4% during the fourth quarter. Two Sigma Investments LP now owns 861,188 shares of the medical device company’s stock valued at $31,020,000 after purchasing an additional 36,475 shares during the last quarter. State of Wyoming boosted its position in Tandem Diabetes Care by 95.9% during the fourth quarter. State of Wyoming now owns 2,996 shares of the medical device company’s stock worth $108,000 after purchasing an additional 1,467 shares during the period. Finally, Shell Asset Management Co. boosted its position in Tandem Diabetes Care by 16.9% during the fourth quarter. Shell Asset Management Co. now owns 26,281 shares of the medical device company’s stock worth $947,000 after purchasing an additional 3,803 shares during the period.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.